Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for InMed Pharmaceuticals (INM) over the last 3 years, with Sep 2025 value amounting to -$137,178.

  • InMed Pharmaceuticals' Cash from Financing Activities fell 116.37% to -$137,178 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 85.48%. This contributed to the annual value of $12.3 million for FY2025, which is 163.66% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Cash from Financing Activities stood at -$137,178, which was down 101.68% from $8.2 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Cash from Financing Activities peaked at $10.9 million during Q3 2021, and registered a low of -$836,144 during Q4 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $338,521 (2024), whereas its average is $1.7 million.
  • Per our database at Business Quant, InMed Pharmaceuticals' Cash from Financing Activities crashed by 117.31% in 2023 and then soared by 4,644,531.25% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Cash from Financing Activities stood at -$836,144 in 2021, then surged by 735.69% to $5.3 million in 2022, then plummeted by 117.31% to -$63,697 in 2023, then reached $338,521 in 2024, then plummeted by 116.37% to -$137,178 in 2025.
  • Its Cash from Financing Activities stands at -$137,178 for Q3 2025, versus $8.2 million for Q2 2025 and $2.9 million for Q1 2025.